Reuters logo
BRIEF-Allergan Plc says new data from phase 2b study supports continued development of cenicriviroc in ongoing phase 3 trial
September 22, 2017 / 12:12 PM / a month ago

BRIEF-Allergan Plc says new data from phase 2b study supports continued development of cenicriviroc in ongoing phase 3 trial

Sept 22 (Reuters) - Allergan Plc

* New data from CENTAUR phase 2b clinical study supports continued development of cenicriviroc (CVC) in ongoing phase 3 AURORA trial

* Allergan Plc - ‍in placebo patients who crossed over to receive CVC during year two, 20% of patients receiving CVC compared to 13% of patients receiving placebo achieved combined endpoint​

* Allergan Plc - ‍new data includes patients who remained on treatment for 2 years, those who received placebo in year 1, crossed-over to CVC for year​ 2

* Allergan - ‍in patients treated for two years, no significant difference in fibrosis improvement observed between CVC, placebo at year 2 in CENTAUR study​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below